Life
Novo Nordisk is warned by the FDA for failing to report side effects
It's the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices.
editorial-staff
1 min read
Updated about 1 month ago
Summary
Summary
- Summary pending editorial review.
Key Facts
- Key facts pending editorial review.
Sources
Key Facts
| Fact | Value |
|---|---|
| Primary source | STAT |
| Source count | 2 |
| First published | 2026-03-10T14:51:35.000Z |
Updates
Update at 13:29 UTC on 2026-03-11
STAT reported Recent developments highlight the FDA's warning to Novo Nordisk and Lilly's strategic investments in China.
Sources: STAT